131 related articles for article (PubMed ID: 38160662)
1. Alpha-2-Macroglobulin Is a Novel Anticancer Agent.
Facchiano F; D'Arcangelo D; Facchiano A
Oncology; 2024; 102(7):641-645. PubMed ID: 38160662
[TBL] [Abstract][Full Text] [Related]
2. Association of salivary alpha 2-macroglobulin levels and clinical characteristics in type 2 diabetes.
Chung TJ; Hsu KY; Chen JH; Liu JS; Chang HW; Li PF; Huang CL; Shieh YS; Lee CH
J Diabetes Investig; 2016 Mar; 7(2):190-6. PubMed ID: 27042270
[TBL] [Abstract][Full Text] [Related]
3. Microparticle alpha-2-macroglobulin enhances pro-resolving responses and promotes survival in sepsis.
Dalli J; Norling LV; Montero-Melendez T; Federici Canova D; Lashin H; Pavlov AM; Sukhorukov GB; Hinds CJ; Perretti M
EMBO Mol Med; 2014 Jan; 6(1):27-42. PubMed ID: 24357647
[TBL] [Abstract][Full Text] [Related]
4. An association between plasma levels of α2-macroglobulin and α1-antitrypsin in PiMM and PiZZ individuals differing in COPD presentation.
Lechowicz U; Martinez-Delgado B; Liu B; Wrenger S; Rozy A; Zdral A; DeLuca DS; Welte T; Janciauskiene S; Chorostowska-Wynimko J
Clin Biochem; 2024 Apr; 126():110736. PubMed ID: 38428450
[TBL] [Abstract][Full Text] [Related]
5. BET inhibitor suppresses melanoma progression
Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
[No Abstract] [Full Text] [Related]
6. Identification of an irreversible PPARγ antagonist with potent anticancer activity.
Peng Y; Zhang Q; Zielinski RM; Howells RD; Welsh WJ
Pharmacol Res Perspect; 2020 Dec; 8(6):e00693. PubMed ID: 33280279
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists down-regulate alpha2-macroglobulin expression by a PPARalpha-dependent mechanism.
González MC; Corton JC; Cattley RC; Herrera E; Bocos C
Biochimie; 2009 Aug; 91(8):1029-35. PubMed ID: 19497347
[TBL] [Abstract][Full Text] [Related]
8. Association of salivary alpha-2-macroglobulin with glycemia and glycated hemoglobin in type 2 diabetes mellitus: a systematic review and meta-analysis study.
Caixeta DC; Pennisi PRC; Moura DV; Nunes MAC; Espindola FS; Blumenberg C; Paranhos LR; Sabino-Silva R
Sao Paulo Med J; 2022; 140(6):818-828. PubMed ID: 36102452
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Yang J; Zaja-Milatovic S; Thu YM; Lee F; Smykla R; Richmond A
Mol Cancer Ther; 2009 Mar; 8(3):636-47. PubMed ID: 19276165
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
[TBL] [Abstract][Full Text] [Related]
11. Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis.
Chen B; Sun D; Qin X; Gao XH
Invest New Drugs; 2021 Aug; 39(4):928-948. PubMed ID: 33501609
[TBL] [Abstract][Full Text] [Related]
12. The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.
Dar AA; Nosrati M; Bezrookove V; de Semir D; Majid S; Thummala S; Sun V; Tong S; Leong SP; Minor D; Billings PR; Soroceanu L; Debs R; Miller JR; Sagebiel RW; Kashani-Sabet M
J Natl Cancer Inst; 2015 Feb; 107(5):. PubMed ID: 25713167
[TBL] [Abstract][Full Text] [Related]
13. Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
Garmpis N; Damaskos C; Garmpi A; Dimitroulis D; Spartalis E; Margonis GA; Schizas D; Deskou I; Doula C; Magkouti E; Andreatos N; Antoniou EA; Nonni A; Kontzoglou K; Mantas D
Anticancer Res; 2017 Oct; 37(10):5355-5362. PubMed ID: 28982843
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
Roy T; Boateng ST; Banang-Mbeumi S; Singh PK; Basnet P; Chamcheu RN; Ladu F; Chauvin I; Spiegelman VS; Hill RA; Kousoulas KG; Nagalo BM; Walker AL; Fotie J; Murru S; Sechi M; Chamcheu JC
Bioorg Chem; 2021 Feb; 107():104595. PubMed ID: 33450548
[TBL] [Abstract][Full Text] [Related]
15. Clinical protein science in translational medicine targeting malignant melanoma.
Gil J; Betancourt LH; Pla I; Sanchez A; Appelqvist R; Miliotis T; Kuras M; Oskolas H; Kim Y; Horvath Z; Eriksson J; Berge E; Burestedt E; Jönsson G; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Horvatovich P; Murillo JR; Sugihara Y; Welinder C; Wieslander E; Lee B; Lindberg H; Pawłowski K; Kwon HJ; Doma V; Timar J; Karpati S; Szasz AM; Németh IB; Nishimura T; Corthals G; Rezeli M; Knudsen B; Malm J; Marko-Varga G
Cell Biol Toxicol; 2019 Aug; 35(4):293-332. PubMed ID: 30900145
[TBL] [Abstract][Full Text] [Related]
16. 3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model.
Paulitschke V; Schicher N; Szekeres T; Jäger W; Elbling L; Riemer AB; Scheiner O; Trimurtulu G; Venkateswarlu S; Mikula M; Swoboda A; Fiebiger E; Gerner C; Pehamberger H; Kunstfeld R
J Invest Dermatol; 2010 Jun; 130(6):1668-79. PubMed ID: 19956188
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine metabolism as a therapeutic target in cutaneous melanoma.
Dany M
Transl Res; 2017 Jul; 185():1-12. PubMed ID: 28528915
[TBL] [Abstract][Full Text] [Related]
18. A Proteomics Approach Identifies RREB1 as a Crucial Molecular Target of Imidazo-Pyrazole Treatment in SKMEL-28 Melanoma Cells.
Iervasi E; Coronel Vargas G; Bachetti T; Tkachenko K; Spallarossa A; Brullo C; Rosano C; Carta S; Barboro P; Profumo A; Ponassi M
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928466
[TBL] [Abstract][Full Text] [Related]
19. Alveolar fluid neutrophil elastase activity in the adult respiratory distress syndrome is complexed to alpha-2-macroglobulin.
Wewers MD; Herzyk DJ; Gadek JE
J Clin Invest; 1988 Oct; 82(4):1260-7. PubMed ID: 2459160
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
